Journal of Clinical Oncology, Vol 19, Issue 14
(July), 2001: 3357-3366
© 2001 American Society for Clinical Oncology
Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol Acetate
By A. Buzdar,
J. Douma,
N. Davidson,
R. Elledge,
M. Morgan,
R. Smith,
L. Porter,
J. Nabholtz,
X. Xiang,
C. Brady
From the University of Texas M.D. Anderson Cancer Center and Baylor College of Medicine, Houston, TX; St Thomas Medical Group, Nashville, TN; Baptist Medical Center, Columbia, SC; Ziekenhuis Rijnstate, Arnhem, the Netherlands; North Middlesex Hospital, London, and St Margaret’s Hospital, Essex, United Kingdom; and Cross Cancer Institute, Edmonton, Alberta, Canada.
Address reprint requests to Aman Buzdar, MD, Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Box 424, 1515 Holcombe Blvd, Houston, TX 77030; email: abuzdar{at}mdanderson.org
PURPOSE: To compare two doses of letrozole (0.5 mg and 2.5 mg every day) and megestrol acetate (40 mg qid) as endocrine therapy in postmenopausal women with advanced breast cancer previously treated with antiestrogens.
PATIENTS AND METHODS: This double-blind, randomized, multicenter, multinational study enrolled 602 patients, all of whom were included in the primary analysis in the protocol. Patients had advanced or metastatic breast cancer with evidence of disease progression while receiving continuous adjuvant antiestrogen therapy, had experienced relapse within 12 months of stopping adjuvant antiestrogen therapy given for at least 6 months, or had experienced disease progression while receiving antiestrogen therapy for advanced disease. Tumors were required to be estrogen receptor– and/or progesterone receptor–positive or of unknown status. Confirmed objective response rate was the primary efficacy variable. Karnofsky Performance Status and European Organization for Research and Treatment of Cancer quality-of-life assessments were collected for 1 year.
RESULTS: There were no statistically significant differences among the three treatment groups for overall objective tumor response. Patients treated with letrozole 0.5 mg had improvements in disease progression (P = .044) and a decreased risk of treatment failure (P = .018), compared with patients treated with megestrol acetate. Letrozole 0.5 mg showed a trend (P = .053) for survival benefit when compared with megestrol acetate. Megestrol acetate was more likely to produce weight gain, dyspnea, and vaginal bleeding, and the letrozole groups were more likely to experience headache, hair thinning, and diarrhea.
CONCLUSION: Given a favorable tolerability profile, once-daily dosing, and evidence of clinically relevant benefit, letrozole is equivalent to megestrol acetate and should be considered for use as an alternative treatment of advanced breast cancer in postmenopausal women after treatment failure with antiestrogens.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
B. MELICHAR, H. KALABOVA, L. KRCMOVA, L. URBANEK, R. HYSPLER, D. SOLICHOVA, K. MELICHAROVA, M. PECKA, and Z. ZADAK
Effect of Aromatase Inhibitors on Lipid Metabolism, Inflammatory Response and Antioxidant Balance in Patients with Breast Carcinoma
Anticancer Res,
August 1, 2009;
29(8):
3337 - 3346.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Guarneri and P. Conte
Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy
Oncologist,
July 1, 2009;
14(7):
645 - 656.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. U. Lin and E. P. Winer
Advances in Adjuvant Endocrine Therapy for Postmenopausal Women
J. Clin. Oncol.,
February 10, 2008;
26(5):
798 - 805.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Sabnis, O. Goloubeva, D. Jelovac, A. Schayowitz, and A. Brodie
Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway Improves Response of Long-term Estrogen-Deprived Breast Cancer Xenografts to Antiestrogens
Clin. Cancer Res.,
May 1, 2007;
13(9):
2751 - 2757.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Colozza, E. de Azambuja, N. Personeni, F. Lebrun, M. J. Piccart, and F. Cardoso
Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer
Oncologist,
March 1, 2007;
12(3):
253 - 270.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Beslija, J Bonneterre, H Burstein, V Cocquyt, M Gnant, P Goodwin, V Heinemann, J Jassem, W. Kostler, M Krainer, et al.
Second consensus on medical treatment of metastatic breast cancer
Ann. Onc.,
February 1, 2007;
18(2):
215 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Mauri, N. Pavlidis, N. P. Polyzos, and J. P. A. Ioannidis
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
J Natl Cancer Inst,
September 20, 2006;
98(18):
1285 - 1291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Linden, S. A. Stekhova, J. M. Link, J. R. Gralow, R. B. Livingston, G. K. Ellis, P. H. Petra, L. M. Peterson, E. K. Schubert, L. K. Dunnwald, et al.
Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer
J. Clin. Oncol.,
June 20, 2006;
24(18):
2793 - 2799.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Altundag and N. K. Ibrahim
Aromatase inhibitors in breast cancer: an overview.
Oncologist,
June 1, 2006;
11(6):
553 - 562.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Neyt, J. Albrecht, and V. Cocquyt
An economic evaluation of Herceptin(R) in adjuvant setting: the Breast Cancer International Research Group 006 trial
Ann. Onc.,
March 1, 2006;
17(3):
381 - 390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Normanno, M. Di Maio, E. De Maio, A. De Luca, A. de Matteis, A. Giordano, F. Perrone, and on behalf of the NCI-Naples Breast Cancer Group
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
Endocr. Relat. Cancer,
December 1, 2005;
12(4):
721 - 747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G A Clines and T A Guise
Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone
Endocr. Relat. Cancer,
September 1, 2005;
12(3):
549 - 583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chan, M. E. Scheulen, S. Johnston, K. Mross, F. Cardoso, C. Dittrich, W. Eiermann, D. Hess, R. Morant, V. Semiglazov, et al.
Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer
J. Clin. Oncol.,
August 10, 2005;
23(23):
5314 - 5322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Boccardo, A. Rubagotti, M. Puntoni, P. Guglielmini, D. Amoroso, A. Fini, G. Paladini, M. Mesiti, D. Romeo, M. Rinaldini, et al.
Switching to Anastrozole Versus Continued Tamoxifen Treatment of Early Breast Cancer: Preliminary Results of the Italian Tamoxifen Anastrozole Trial
J. Clin. Oncol.,
August 1, 2005;
23(22):
5138 - 5147.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Howell and A. M Wardley
Overview of the impact of conventional systemic therapies on breast cancer
Endocr. Relat. Cancer,
July 1, 2005;
12(Supplement_1):
S9 - S16.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Brueggemeier, J. C. Hackett, and E. S. Diaz-Cruz
Aromatase Inhibitors in the Treatment of Breast Cancer
Endocr. Rev.,
May 1, 2005;
26(3):
331 - 345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kudachadkar and R. M. O'Regan
Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer
CA Cancer J Clin,
May 1, 2005;
55(3):
145 - 163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Strasser-Weippl and P. E. Goss
Advances in Adjuvant Hormonal Therapy for Postmenopausal Women
J. Clin. Oncol.,
March 10, 2005;
23(8):
1751 - 1759.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. P. Winer, C. Hudis, H. J. Burstein, A. C. Wolff, K. I. Pritchard, J. N. Ingle, R. T. Chlebowski, R. Gelber, S. B. Edge, J. Gralow, et al.
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004
J. Clin. Oncol.,
January 20, 2005;
23(3):
619 - 629.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Tobias
Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention
Ann. Onc.,
December 1, 2004;
15(12):
1738 - 1747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bottomley, L. Biganzoli, T. Cufer, R. E. Coleman, C. Coens, F. Efficace, H. A. Calvert, T. Gamucci, C. Twelves, P. Fargeot, et al.
Randomized, Controlled Trial Investigating Short-Term Health-Related Quality of Life With Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study
J. Clin. Oncol.,
July 1, 2004;
22(13):
2576 - 2586.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sonmezer and K. Oktay
Fertility preservation in female patients
Hum. Reprod. Update,
May 1, 2004;
10(3):
251 - 266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Campos
Aromatase Inhibitors for Breast Cancer in Postmenopausal Women
Oncologist,
April 1, 2004;
9(2):
126 - 136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. P. Mamounas
NSABP Breast Cancer Clinical Trials: Recent Results and Future Directions
Clin. Med. Res.,
October 1, 2003;
1(4):
309 - 326.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Waeber, M. Castiglione-Gertsch, D. Dietrich, B. Thurlimann, A. Goldhirsch, K. W. Brunner, and M. M. Borner
Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation
Ann. Onc.,
August 1, 2003;
14(8):
1215 - 1221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. U. Buzdar
Advances in Endocrine Treatments for Postmenopausal Women with Metastatic and Early Breast Cancer
Oncologist,
August 1, 2003;
8(4):
335 - 341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Piccart, L. M. Parker, and K. I. Pritchard
Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer
Ann. Onc.,
July 1, 2003;
14(7):
1017 - 1025.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. E. Smith and M. Dowsett
Aromatase Inhibitors in Breast Cancer
N. Engl. J. Med.,
June 12, 2003;
348(24):
2431 - 2442.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Goodwin, J. T. Black, L. J. Bordeleau, and P. A. Ganz
Health-Related Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer--Taking Stock
J Natl Cancer Inst,
February 19, 2003;
95(4):
263 - 281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Tominaga, I. Adachi, Y. Sasaki, T. Tabei, T. Ikeda, Y. Takatsuka, M. Toi, T. Suwa, and Y. Ohashi
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer
Ann. Onc.,
January 1, 2003;
14(1):
62 - 70.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. I. Pritchard
Endocrine Therapy of Advanced Disease: Analysis and Implications of the Existing Data
Clin. Cancer Res.,
January 1, 2003;
9(1):
460s - 467s.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. U. Buzdar
Pharmacology and Pharmacokinetics of the Newer Generation Aromatase Inhibitors
Clin. Cancer Res.,
January 1, 2003;
9(1):
468s - 472s.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. A. Ligibel and E. P. Winer
Clinical Differences among the Aromatase Inhibitors
Clin. Cancer Res.,
January 1, 2003;
9(1):
473s - 479s.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Beltran, R. Colomer, A Lipton, S.M. Ali, and K. Leitzel
Does HER-2 Status Predict Only a Decreased Response to Hormone Therapy in Advanced Breast Cancer, or Does It Also Predict the Extent of Metastatic Disease?
J. Clin. Oncol.,
December 1, 2002;
20(23):
4605 - 4606.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. C. Henderson
A Rose Is No Longer a Rose
J. Clin. Oncol.,
August 15, 2002;
20(16):
3365 - 3368.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. P. Winer, C. Hudis, H. J. Burstein, R. T. Chlebowski, J. N. Ingle, S. B. Edge, E. P. Mamounas, J. Gralow, L. J. Goldstein, K. I. Pritchard, et al.
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor-Positive Breast Cancer: Status Report 2002
J. Clin. Oncol.,
August 1, 2002;
20(15):
3317 - 3327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Long, D. Jelovac, A. Thiantanawat, and A. M. Brodie
The Effect of Second-Line Antiestrogen Therapy on Breast Tumor Growth after First-Line Treatment with the Aromatase Inhibitor Letrozole: Long-Term Studies Using the Intratumoral Aromatase Postmenopausal Breast Cancer Model
Clin. Cancer Res.,
July 1, 2002;
8(7):
2378 - 2388.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Morrow and W. Gradishar
Recent developments: Breast cancer
BMJ,
February 16, 2002;
324(7334):
410 - 414.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. U. Buzdar, H. Mouridsen, and H. A. Chaudri-Ross
Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy
J. Clin. Oncol.,
February 1, 2002;
20(3):
876 - 878.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cocconi
False Shortening of Time to Progression in Letrozole 2.5-mg Dose?
J. Clin. Oncol.,
December 1, 2001;
19(23):
4353 - 4353.
[Full Text]
|
|
|
|
|
|
|
J. R. Mackey, A. A. Joy, A. U. Buzdar, C. Brady, and H. A. Chaudri-Ross
Letrozole in Second-Line Therapy of Advanced Breast Cancer: More Questions Than Answers
J. Clin. Oncol.,
December 1, 2001;
19(23):
4353 - 4355.
[Full Text]
|
|
|
|
|
|
|
P. E. Lonning
Aromatase inhibitors and inactivators in breast cancer
BMJ,
October 20, 2001;
323(7318):
880 - 881.
[Full Text]
[PDF]
|
|
|
|
